SO
AVBP icon

STRS Ohio’s ArriVent BioPharma AVBP Stock Holding History

STRS Ohio’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,700
Closed -$40K – 2076
2024
Q3 		$40K Hold
1,700
– – ﹤0.01% 1835
2024
Q2 		$31.5K Hold
1,700
– – ﹤0.01% 1843
2024
Q1 		$30K Buy
+1,700
New +$34.3K ﹤0.01% 1820

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

STRS Ohio's AVBP Position: Q4 2024 in Review

STRS Ohio sold out of ArriVent BioPharma (AVBP) in Q4 2024, closing a stake of 1,700 shares — an estimated $40K sold.

STRS Ohio first reported a position in AVBP in Q1 2024 and held it in 3 quarters. The position peaked at $40K in Q3 2024. 80 funds tracked by Wall St. Rank hold AVBP as of Q4 2024.

  • STRS Ohio reported no remaining ArriVent BioPharma position as of Q4 2024 after selling out during the quarter.
  • STRS Ohio sold 1,700 ArriVent BioPharma shares in Q4 2024, an estimated $40K.
  • STRS Ohio first reported a position in ArriVent BioPharma in Q1 2024 and held it in 3 quarters.
  • STRS Ohio's ArriVent BioPharma position peaked at $40K in Q3 2024.
  • 80 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q4 2024.

Based on STRS Ohio's 13F filing for Q4 2024, filed 28 May 2025.